证券代码：600774 股票简称：汉商集团 编号：2026-002 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示: 登录新浪财经APP 搜索【信披】查看更多考评等级 二、上年同期经营业绩和财务状况 ● 业绩预告的具体适用情形：净利润为负值。 ● 汉商集团股份有限公司（以下简称"公司"）预计2025年年度实现归属于母公司所有者的净利润-9000 万元到-6000万元，与上年同期（法定披露数据）相比，将继续亏损。预计2025年年度实现归属于母公 司所有者的扣除非经常性损益后的净利润-4998万元到-1998万元。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日 （二）业绩预告情况 经财务部门初步测算，并就业绩预告有关事项与年审会计师及评估师进行了预沟通，预计2025年年度实 现归属于母公司所有者的净利润-9000万元到-6000万元，与上年同期相比，将继续亏损。 预计2025年年度实现归属于母公司所有者的扣除非经常性损益后的净利润-4998万元到-1998万元。 （三）公司本次 ...

Core Viewpoint - The company, Han Commercial Group Co., Ltd., anticipates a continued loss for the fiscal year 2025, projecting a net profit attributable to shareholders of between -90 million and -60 million yuan, indicating a worsening financial situation compared to the previous year [2][3]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [3]. - The company expects a net profit attributable to shareholders of between -90 million and -60 million yuan for 2025, continuing the trend of losses from the previous year [2][3]. - The projected net profit, excluding non-recurring gains and losses, is estimated to be between -49.98 million and -19.98 million yuan [4]. Group 2: Previous Year’s Financial Performance - In the previous year, the total profit was -5.4686 million yuan, with a net profit attributable to shareholders of -14.5872 million yuan [6]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -38.0898 million yuan [6]. - The earnings per share for the previous year were -0.0494 yuan [7]. Group 3: Reasons for Expected Loss - The company adheres to the "Enterprise Accounting Standards" and related accounting policies, conducting year-end impairment tests on relevant assets [8]. - A significant factor contributing to the expected loss for 2025 is the planned goodwill impairment related to the Wuhan Huake Reproductive Obstetrics Hospital asset group, estimated between 80 million and 90 million yuan [8]. - The final amount of goodwill impairment will be determined by the evaluation and audit conducted by the company's appointed assessment and audit institutions [8].

格隆汇1月30日丨汉商集团(600774.SH)公布，公司预计2025年年度实现归属于母公司所有者的净利 润-9000万元到-6000万元，与上年同期（法定披露数据）相比，将继续亏损。预计2025年年度实现归属 于母公司所有者的扣除非经常性损益后的净利润-4998万元到-1998万元。 ...

证券代码：600774 股票简称：汉商集团 编号：2026-002 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况 经财务部门初步测算，并就业绩预告有关事项与年审会计师及评估师进 行了预沟通，预计 2025 年年度实现归属于母公司所有者的净利润-9000 万元 到-6000 万元，与上年同期相比，将继续亏损。 预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益后的净利 润-4998 万元到-1998 万元。 汉商集团股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 一、本期业绩预告情况 （三）公司本次所预计的业绩未经注册会计师审计。 业绩预告的具体适用情形：净利润为负值。 汉商集团股份有限公司（以下简称"公司"）预计 2025 年年度实现 归属于母公司所有者的净利润-9000 万元到-6000 万元，与上年同期 （法定披露数据）相比，将继续亏损。预计 2025 年年度实现归属于 母公司所有者的扣除非经常性 ...

南财智讯1月30日电，汉商集团发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-9000万元至-6000万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为-4998万 元至-1998万元。公司严格遵循《企业会计准则》及相关会计政策，基于谨慎性原则，对相关资产进行 年末减值测试并计提相应减值准备。在初步评估的基础上，公司拟对武汉华科生殖妇产医院资产组计提 商誉减值准备，预计计提金额在8000万元至9000万元之间，该非现金性计提事项是导致2025年度净利润 为负的主要原因。最终商誉减值金额将由公司聘请的评估机构及审计机构进行评估和审计后确定。届 时，公司将按照《上海证券交易所股票上市规则》履行信息披露义务。 ...

扬子晚报网1月26日讯(记者范晓林)今天是周一，上周五锋龙股份（002931）18连板，江化微（603078）5连板，白银有色（601212）4连板，巨力索具 （002342）3连板，汉商集团（600774）5天3板。指数尾盘震荡拉升，北证50指数大涨超3%。沪深两市成交额3.09万亿，较上一个交易日放量3935亿。盘 面上，市场热点快速轮动，全市场超3900只个股上涨。板块方面，光伏、商业航天、黄金、AI应用端领涨。日前，OpenAI已开始在聊天机器人ChatGPT 平台为数十家广告商提供广告位服务，首批广告预计于2月初上线。AI应用端表现持续回暖，浙文互联（600986）反包涨停走出11天5板，带动易点天下 （301171）、蓝色光标（300058）、天龙集团（300063）、岩山科技（002195）等前期人气股不同程度展开反弹。 A.利好精选 18连板锋龙股份：2025年12月25日至2026年1月23日股价涨幅405.74%自1月26日开市起停牌核查 锋龙股份(002931.SZ)发布股票交易异常波动风险提示暨停牌核查的公告，公司股票自2025年12月25日至2026年1月23日已连续17个交易日涨停 ...

Group 1 - The chemical pharmaceutical sector increased by 0.91% on January 23, with Guangshantang leading the gains [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] - Guangshantang's stock price rose by 20.00% to 96.28, with a trading volume of 185,500 shares [1] Group 2 - The main funds in the chemical pharmaceutical sector experienced a net outflow of 487 million yuan, while retail investors saw a net inflow of 1.12 billion yuan [2] - The stock performance of several companies showed varied results, with some experiencing declines, such as Xingqi Eye Medicine down 4.86% [2] - The trading volume and turnover for various companies in the sector were significant, with notable figures such as 1.62 billion yuan for Xingqi Eye Medicine [2] Group 3 - Guangshantang had a net inflow of 396 million yuan from main funds, while retail investors had a net outflow of 136 million yuan [3] - Other companies like Hancheng Group and Shutaishen also showed significant net inflows and outflows, indicating varied investor sentiment [3] - The data reflects a mixed investment environment within the chemical pharmaceutical sector, with both institutional and retail investors actively participating [3]

| 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 300436 | 广生堂 | 1 | 20.00 | 153亿 | 8.00 | | 301093 | 中三股份 | 资 | 12.00 | 138亿 | 63.89 | | 600774 | 汉商集团 * | | 10.00 | 34.08亿 | 26.37 | | 300683 | 海特生物 | 资 | 7.92 | 43.71亿 | 20.41 | | 688759 | 必贝特-U | 1 | 6.64 | 249亿 | 90.09 | | 300204 | 舒泰神 | 1 | 5.78 | 136亿 | 4.58 | | 688222 | 成都先导 | 中 | 5.42 | 138亿 | 46.78 | | 000078 | 海王生物 | 1 | 5.23 | 101亿 | 10.40 | | 600998 | 九州通 | 1 | 4.71 | 280亿 | 8.59 | | 301230 | 泓博医药 | | 4.60 | 67.60亿 | 62 ...

Group 1 - The A-share market saw a significant decline in innovative drug concept stocks, with notable drops including Aidi Pharmaceutical down over 11% and Yifang Bio down over 5% [1] - Other companies such as Xingqi Pharmaceutical, Zhenbaodao, and Dize Pharmaceutical experienced declines of over 4%, while Rongchang Bio, Hanshang Group, Yuekang Pharmaceutical, Xinlitai, Haishike, Shanghai Yizhong, and Kanghong Pharmaceutical fell by over 3% [1] Group 2 - Aidi Pharmaceutical (688488) reported a decline of 11.33%, with a total market value of 7.835 billion and a year-to-date increase of 14.02% [2] - Yifang Bio (688382) decreased by 5.99%, with a market capitalization of 15 billion and a year-to-date decline of 4.99% [2] - Xingqi Pharmaceutical (300573) fell by 4.82%, with a market value of 19.4 billion and a year-to-date increase of 12.01% [2] - Zhenbaodao (603567) dropped by 4.74%, with a market capitalization of 7.951 billion and a year-to-date decline of 5.38% [2] - Dize Pharmaceutical (688192) decreased by 4.19%, with a market value of 27.5 billion and a year-to-date increase of 2.78% [2] - Rongchang Bio (688331) fell by 3.98%, with a market capitalization of 56.1 billion and a year-to-date increase of 27.79% [2] - Hanshang Group (600774) decreased by 3.93%, with a market value of 3.101 billion and a year-to-date increase of 14.99% [2] - Yuekang Pharmaceutical (688658) dropped by 3.84%, with a market capitalization of 12 billion and a year-to-date increase of 18.40% [2] - Xinlitai (002294) fell by 3.32%, with a market value of 55.5 billion and a year-to-date increase of 0.48% [2] - Haishike (002653) decreased by 3.23%, with a market capitalization of 56.1 billion and a year-to-date decline of 2.44% [2] - Shanghai Yizhong (688091) dropped by 3.17%, with a market value of 11.2 billion and a year-to-date increase of 15.60% [2] - Kanghong Pharmaceutical (002773) fell by 3.15%, with a market capitalization of 29.5 billion and a year-to-date increase of 6.81% [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600774 股票简称：汉商集团 编号：2026-001 汉商集团股份有限公司 重要内容提示: ● 汉商集团股份有限公司（以下简称"公司"）股票交易连续3个交易日内（2026年1月16日、2026年1月 19日、2026年1月20日）收盘价格涨幅偏离值累计超过20%。根据《上海证券交易所交易规则》的相关 规定，公司股票交易属于异常波动情况。 ● 截至本公告披露日，公司、控股股东及实际控制人除前期发布的重大资产重组事项外，不存在其他应 披露而未披露的重大事项，包括但不限于重大资产重组、股份发行、收购、债务重组、业务重组、资产 剥离、资产注入、股份回购、股权激励、破产重整、重大业务合作、引进战略投资者等重大事项。 ● 在公司本次股票交易异常波动期间，控股股东及实际控制人不存在买卖公司股票的情况。 一、股票交易异常波动的具体情况 股票交易连续3个交易日内（2026年1月16日、2026年1月19日、2026年1月20日）收盘价格涨幅偏离值累 计超过20％。根据《上海证券交易所交易规则》的相关规定，公司股票交易属于异常波动情况。 二、公司关注并核实的相关情况 ...